Pipobroman

This page contains recent news articles, when available, and an overview of Pipobroman but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

Pipobroman
(when available)

Pharmacology and use:
Pipobroman is an antineoplastic agent. Specifically it is a piperazine derivative with a chemical structure close to that of many DNA alkylating agents. Pipobroman has well documented clinical activity against polycythemia vera and essential thrombocythemia. For the treatment of polycythaemia vera and refractory chronic myeloid leukaemia.

Mechanism Of Action:
The mechanism of action is uncertain but pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death.

News Articles on Pipobroman

… , Diagnostik und Therapie: Pipobroman im Ausland zugelassen  -  Jan 25, 2008
Zum leukämogenen Risiko von Pipobroman bei der ET gibt es Langzeitdaten, die kein erhöhtes Risiko für eine Leukämie bei der ET gezeigt haben (3). ... Deutsches Ärzteblatt

Leukemia - Comparison of whole blood vs purified blood granulocytes...  -  Feb 15, 2007
Twelve MPD patients (five PV, five ET and two IMF) had been receiving cytoreductive treatment (pipobroman or hydroxyurea); all other patients were examined ... Nature.com

Essential thrombocythemia in young individuals: frequency and risk …  -  Apr 12, 2007
...of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. ... Nature.com

Alabama Administrative Code - 540-X-4-.07 Emergency Prescription …  -  Aug 17, 2005
Uracil Mustard (II) Nitrosoureas I Lomustine II Carmustine III Streptozocin (III) Thiotepa (IV) Busulfan (V) Pipobroman (VI) Cisplatin (iii) Antimetabolite ... Pay-Per-View - Alabama Administrative Code - Loislaw

Alabama Administrative Code - 680-X-2-.26 Emergency Prescription …  -  Aug 17, 2005
Streptozocin (III) Thiotepa (IV) Busulfan (V) Pipobroman (VI) Cisplatin (iii) Antimetabolite (I) Methotrexate (II) Fluorouracil and Floxuridine (III) ... Pay-Per-View - Alabama Administrative Code - Loislaw

Acute Leukemia in Polycythemia Vera  -  Jul 1, 2005
Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370-3377. ... Pay-Per-View - Clinical Oncology Report - Factiva, from Dow Jones

Annales de Biologie Clinique  -  Aug 27, 2005
à un traitement de fond cytoréducteur par, notamment, le phosphore 32 (P32) chez le sujet âgé, le pipobroman (Vercyte ® ) ou l'hydroxyurée (Hydréa ® ). ... john-libbey-eurotext.fr

Brand Names/Synonyms:
Pipobroman is also known by the following brand names and/or synonymsA 1803; A-8103; Amedel; NSC-25154; Pipobroman; Pipobroman [Usan:Inn]; Pipobromanum [Inn-Latin]; Vercyte

Drug Category:
Pipobroman is categorized under the following by the FDA: Antineoplastic Agents; ATC:L01AX02

Dosage Forms:
TABLET (25 mg)

Absorption:
Well absorbed from the GI tract.

Interactions:
Not Available



Chemical IUPAC Name:
3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]-propan-1-one





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy